Solid Biosciences Inc. SLDB Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Returns | ||||||
| Return on equity | -57.4%+52.5pp | -109.9%-23.1pp | -86.8%-18.6pp | -68.2%-13.0pp | -55.3%+39.3pp | |
| Return on assets | -50%+32.8pp | -82.8%-14.0pp | -68.8%-11.7pp | -57.1%-10.0pp | -47.1%+23.4pp | |
| Return on invested capital | -191.5%-30.4pp | -161.1%-50.2pp | -111%+7.4pp | -118.3%+7.9pp | -126.2%+36.0pp | |
| Liquidity | ||||||
| Current ratio | 13.1×+7.0× | 6.1×-0.6× | 6.7×-2.6× | 9.3×-1.6× | 10.9×+5.7× | |
| Quick ratio | 13.1×+7.0× | 6.1×-0.6× | 6.7×-2.6× | 9.3×-1.6× | 10.9×+5.7× | |
| Cash ratio | 9.8×+8.0× | 1.8×+0.1× | 1.7×-3.0× | 4.7×-2.7× | 7.3×+4.7× | |
| Leverage | ||||||
| Debt-to-equity | 0.1×-0.1× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×-0.1× | |
| Debt-to-assets | 0×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×-0.1× | |
| Per Share | ||||||
| Book value per share | $3.41+65.6% | $2.06-10.9% | $2.31-15.9% | $2.74-38.2% | $4.44+32.0% | |
| Valuation | ||||||
| Market capitalization | $872.26M+135% | $439.41M-8.5% | $480.45M+27.7% | $376.34M+31.3% | $286.72M+79.4% | |
| Enterprise value | $595.83M+223% | $400.67M-9.1% | $441.03M+69.3% | $260.46M+161% | $99.72M-3.9% | |
| Price / book | 2.3×+1.1× | 2.4×+0.2× | 2.2×+0.7× | 1.5×+0.5× | 1×-0.2× | |
| Free cash flow yield | -19.8%+9.1pp | -35.8%-8.1pp | -27.7%+5.1pp | -32.8%+4.7pp | -37.4%+25.6pp | |
| Earnings yield | -22%+15.6pp | -39.7%-4.9pp | -34.8%+6.2pp | -40.9%+7.8pp | -48.7%+29.3pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Solid Biosciences Inc.'s ratios come from?
- Every ratio is computed from Solid Biosciences Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
